CKD-828 Primary Hypertension Trial(Dose-selection)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
S-Amlodipine, Telmisartan
S-Amlodipine
Telmisartan
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring CKD-828, Hypertension, Primary Hypertension, S-Amlodipine, Telmisartan, Amlodipine, Factorial, Phase 2
Eligibility Criteria
Inclusion Criteria:
- age 18 years or older
- stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and <=115 mmHg
- ability to provide written informed consent
Exclusion Criteria:
- severe hypertension defined as: a mean seated cuff diastolic blood pressure >=116mmHg or a mean seated cuff systolic blood pressure >=200mmHg
- known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
- has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
- has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
- Type I Diabets Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8%
- known severe or malignant retinopathy
- hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5
- acute or chronic inflammatory status need to treatment
- need to additional antihypertensive drugs during the study
- need to concomitant medications known to affect blood pressure during the study
- history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
- known hypersensitivity related to either study drug
- history of drug or alcohol dependency
- any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, currently active gatritis, ulcers of gastrointetinal/rectal bleeding, impaired pancreatic fuction such as pancreatitis,obstructions of the urinary tract or difficulty in voiding)
- cannot swallow investigational products
- administration of other study drugs within 4 weeks prior to randomization
- premenopausal women(last menstration < 1year) not using adequte contraception, pregnant or breast-feeding
- history of malignancy including leukemia and lymphoma within the past 5 years
- in investigator's judgment
Sites / Locations
- Hallym University Sacred Heart Hospital
- Soonchunhyang University Hospital in Bucheon
- Kosin University Gospel Hospital
- Chungbuk National Uiversity Hospital
- Daegu Catholic University Medical Center
- Keimyung University Dongsan Medical Center
- DonGuk University International Hospital
- National Health Insurance Corporation Ilsan Hospital
- Chonnam National University Hospital
- Gachon University Gil Medical Center
- Chonbuk National University Hospital
- Pusan National University Hospital
- Seoul National University Bundang Hospital
- Ewha Womans University Hospital
- Gangnam Severance Hospital
- Kandong Sacred Heart Hospital
- Korea University Guro Hospital
- Kyung Hee University Medical Center
- Seoul St. Mary's Hospital, The catholic University of Korea
- Severance Hospital
- SMG-SNU Boramae Medical Center
- Soon Chun Hyang University Hospital
- St. Paul's Hospital, The catholic University of Korea
- Ajou University Hospital
- Uijeongbu St. Mary's Hospital, The catholic University of Korea
- Wonju Christian Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm Type
Experimental
Experimental
Experimental
Experimental
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
S-Amlodipine 2.5mg + Telmisartan 40mg
S-Amlodipine 2.5mg + Telmisartan 80mg
S-Amlodipine 5mg + Telmisartan 40mg
S-Amlodipine 5mg + Telmisartan 80mg
S-Amlodipine 2.5mg
S-Amlodipine 5mg
Telmisartan 40mg
Telmisartan 80mg
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Mean Sitting Diastolic Blood Pressure(MSDBP)
Secondary Outcome Measures
Mean Sitting Diastolic Blood Pressure(MSDBP)
Mean Sitting Systolic Blood Pressure(MSSBP)
Response rate
Reduction of SBP ≥ 20mmHg, DBP ≥ 10mmHg
Control rate
Reduction SBP < 140mmHg, DBP < 90mmHg
Full Information
NCT ID
NCT01128322
First Posted
May 20, 2010
Last Updated
April 22, 2011
Sponsor
Chong Kun Dang Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT01128322
Brief Title
CKD-828 Primary Hypertension Trial(Dose-selection)
Official Title
A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
July 2010 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Chong Kun Dang Pharmaceutical
4. Oversight
5. Study Description
Brief Summary
The aim of this trial is to determine the best dose combination of S-Amlodipine and Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a once daily regimen of various combinations of S-Amlodipine and Telmisartan, compared to their monotherapy components and placebo, in patients with stage I or II essential hypertension(a mean seated cuff diastolic blood pressure >=95 and <=115 mmHg).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
CKD-828, Hypertension, Primary Hypertension, S-Amlodipine, Telmisartan, Amlodipine, Factorial, Phase 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
430 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
S-Amlodipine 2.5mg + Telmisartan 40mg
Arm Type
Experimental
Arm Title
S-Amlodipine 2.5mg + Telmisartan 80mg
Arm Type
Experimental
Arm Title
S-Amlodipine 5mg + Telmisartan 40mg
Arm Type
Experimental
Arm Title
S-Amlodipine 5mg + Telmisartan 80mg
Arm Type
Experimental
Arm Title
S-Amlodipine 2.5mg
Arm Type
Active Comparator
Arm Title
S-Amlodipine 5mg
Arm Type
Active Comparator
Arm Title
Telmisartan 40mg
Arm Type
Active Comparator
Arm Title
Telmisartan 80mg
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
S-Amlodipine, Telmisartan
Intervention Type
Drug
Intervention Name(s)
S-Amlodipine
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Mean Sitting Diastolic Blood Pressure(MSDBP)
Time Frame
After 8 weeks of treatment
Secondary Outcome Measure Information:
Title
Mean Sitting Diastolic Blood Pressure(MSDBP)
Time Frame
After 4 weeks of treatment
Title
Mean Sitting Systolic Blood Pressure(MSSBP)
Time Frame
After 4 weeks and 8 weeks of treatment
Title
Response rate
Description
Reduction of SBP ≥ 20mmHg, DBP ≥ 10mmHg
Time Frame
After 4 weeks and 8 weeks of treatment
Title
Control rate
Description
Reduction SBP < 140mmHg, DBP < 90mmHg
Time Frame
After 4 weeks and 8 weeks of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age 18 years or older
stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and <=115 mmHg
ability to provide written informed consent
Exclusion Criteria:
severe hypertension defined as: a mean seated cuff diastolic blood pressure >=116mmHg or a mean seated cuff systolic blood pressure >=200mmHg
known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
Type I Diabets Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8%
known severe or malignant retinopathy
hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5
acute or chronic inflammatory status need to treatment
need to additional antihypertensive drugs during the study
need to concomitant medications known to affect blood pressure during the study
history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
known hypersensitivity related to either study drug
history of drug or alcohol dependency
any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, currently active gatritis, ulcers of gastrointetinal/rectal bleeding, impaired pancreatic fuction such as pancreatitis,obstructions of the urinary tract or difficulty in voiding)
cannot swallow investigational products
administration of other study drugs within 4 weeks prior to randomization
premenopausal women(last menstration < 1year) not using adequte contraception, pregnant or breast-feeding
history of malignancy including leukemia and lymphoma within the past 5 years
in investigator's judgment
Facility Information:
Facility Name
Hallym University Sacred Heart Hospital
City
Anyang
Country
Korea, Republic of
Facility Name
Soonchunhyang University Hospital in Bucheon
City
Bucheon
Country
Korea, Republic of
Facility Name
Kosin University Gospel Hospital
City
Busan
Country
Korea, Republic of
Facility Name
Chungbuk National Uiversity Hospital
City
Cheongju
Country
Korea, Republic of
Facility Name
Daegu Catholic University Medical Center
City
Daegu
Country
Korea, Republic of
Facility Name
Keimyung University Dongsan Medical Center
City
Daegu
Country
Korea, Republic of
Facility Name
DonGuk University International Hospital
City
Goyang
Country
Korea, Republic of
Facility Name
National Health Insurance Corporation Ilsan Hospital
City
Goyang
Country
Korea, Republic of
Facility Name
Chonnam National University Hospital
City
Gwangju
Country
Korea, Republic of
Facility Name
Gachon University Gil Medical Center
City
Inchon
Country
Korea, Republic of
Facility Name
Chonbuk National University Hospital
City
Jeonju
Country
Korea, Republic of
Facility Name
Pusan National University Hospital
City
Pusan
Country
Korea, Republic of
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
Country
Korea, Republic of
Facility Name
Ewha Womans University Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Gangnam Severance Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Kandong Sacred Heart Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Korea University Guro Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Kyung Hee University Medical Center
City
Seoul
Country
Korea, Republic of
Facility Name
Seoul St. Mary's Hospital, The catholic University of Korea
City
Seoul
Country
Korea, Republic of
Facility Name
Severance Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
SMG-SNU Boramae Medical Center
City
Seoul
Country
Korea, Republic of
Facility Name
Soon Chun Hyang University Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
St. Paul's Hospital, The catholic University of Korea
City
Seoul
Country
Korea, Republic of
Facility Name
Ajou University Hospital
City
Suwon
Country
Korea, Republic of
Facility Name
Uijeongbu St. Mary's Hospital, The catholic University of Korea
City
Uijeongbu
Country
Korea, Republic of
Facility Name
Wonju Christian Hospital
City
Wonju
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
CKD-828 Primary Hypertension Trial(Dose-selection)
We'll reach out to this number within 24 hrs